MAP2K7 and breast carcinoma: However, in contrast to the positive relationship between MEK-ERK signaling and PD-L1 expression observed in most studies, MEK inhibitors are unable to change the PD-L1 expression in melanoma (282), and even increase the levels of PD-L1 in breast cancer and NSCLC cells (283, 284).